High-throughput Identification of Membrane Protein MAbs

膜蛋白单克隆抗体的高通量鉴定

• 批准号: 8831071
• 负责人: Benjamin Jacob Doranz
• 金额: $ 22.48万
• 依托单位: INTEGRAL MOLECULAR
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8831071
• 关键词: Abbreviations; Biomedical Research; Cell Surface Proteins; Cell membrane; Cell surface; Cells; Complement; Development; Diagnostic; Diagnostics Research; Epitopes; Exhibits; FDA approved; Goals; Human; Human Cell Line; Immunization; Industry; Libraries; Membrane; Membrane Proteins; Methods; Molecular; Molecular Conformation; Monoclonal Antibodies; Mutation; Nutrient; Orphan; Performance; Phage Display; Pharmaceutical Preparations; Phase; Plasmids; Protein Array; Proteins; Proteome; Public Health; Qualifying; Reagent; Reproducibility; Services; Signal Transduction; Source; Specificity; Staining method; Stains; Surface; System; Technology; Testing; Therapeutic; Therapeutic Agents; Therapeutic Monoclonal Antibodies; Time; Tissues; United States National Institutes of Health; cell type; commercial application; human disease; novel strategies; protein expression; public health relevance; research study; screening; success; therapeutic development; trafficking

DESCRIPTION (provided by applicant): Membrane proteins control the flow of information, nutrients, and signals through the cell membrane, and are the targets for more than 40% of FDA-approved drugs. Monoclonal antibodies (MAbs) that target membrane proteins can be exceptionally useful in research, diagnostic, and therapeutic applications, but for most membrane proteins there are no MAbs that recognize the native protein on the cell surface. The need for such MAbs has been recognized by industry and the NIH, but efforts to identify such MAbs are limited by the difficulty in expressing and purifying membrane proteins in exogenous systems and by conventional MAb isolation strategies that typically focus on one target at a time. A novel approach to identify membrane protein MAbs in a high-throughput manner is needed to derive MAbs against the entire human membrane proteome. Here we propose a platform technology that can be used to rapidly isolate MAbs against structurally-intact membrane proteins for therapeutic development, diagnostics, and biomedical research.

描述（由申请人提供）：膜蛋白控制信息、营养物质和信号通过细胞膜的流动，并且是超过40%的FDA批准药物的靶点。靶向膜蛋白的单克隆抗体（MAb）在研究、诊断和治疗应用中特别有用，但是对于大多数膜蛋白，没有识别细胞表面上的天然蛋白的MAb。工业界和NIH已经认识到对这种单克隆抗体的需求，但是鉴定这种单克隆抗体的努力受到在外源系统中表达和纯化膜蛋白的困难以及通常一次集中于一个靶标的常规单克隆抗体分离策略的限制。需要一种以高通量方式鉴定膜蛋白单克隆抗体的新方法来衍生针对整个人类膜蛋白质组的单克隆抗体。在这里，我们提出了一个平台技术，可用于快速分离单克隆抗体对结构完整的膜蛋白的治疗开发，诊断和生物医学研究。